The NCI RAS Initiative has a "hub-and-spokes" structure, in that its scientists work both independently and in collaboration with academic and commercial entities. The list of RAS Initiative publications below reflects the balance between the public responsibilities of the National Cancer Institute and the requirements of our external partners.
Authors who names are marked with an asterisk (*) are part of the RAS Initiative.
Discovery of BBO-8520, a first-in-class direct and covalent dual inhibitor of GTP-bound (ON) and GDP-bound (OFF) KRASG12C
Maciag AE*, Stice JP, Wang B, Sharma AK*, Chan AH*, Lin K, Singh D, Dyba M*, Yang Y, Setoodeh S, Smith BP*, Ju JH, Jeknic S, Rabara D*, Zhang Z, Larsen EK*, Esposito D*, Denson JP*, Ranieri M, Meynardie M, Mehdizadeh S, Alexander PA*, Abreu Blanco M*, Turner DM*, Xu R, Lightstone FC, Wong KK, Stephen AG*, Wang K, Simanshu DK*, Sinkevicius KW, Nissley DV*, Wallace E, McCormick F, Beltran PJ
Cancer Discov, Dec 2024
PubMed ID: 39642212
The prominent pervasive oncogenic role and tissue-specific permissiveness of RAS gene mutations supported by DepMap high-throughput CRISPR screening data
Yi M*, Soppet D*, McCormick F, Nissley DV*
Sci Rep,14(1):25452, Oct 2024
PubMed ID: 39455841
Two hearts beat as one: the debate over RAS dimers continues
Stephen AG*
Trends Biochem Sci, Oct 2024
PubMed ID: 39358051
KRas4b-Calmodulin interaction with membrane surfaces: role of headgroup, acyl chain, and electrostatics
Shree S, McLean MA, Stephen AG*, Sligar SG
Biochemistry, Oct 2024
PubMed ID: 39382513
Beyond KRAS(G12C): biochemical and computational characterization of sotorasib and adagrasib binding specificity and the critical role of H95 and Y96
Mahran R, Kapp JN, Valtonen S, Champagne A*, Ning J, Gillette W*, Stephen AG*, Hao F, Plückthun A, Härmä H, Pantsar T, Kopra K
ACS Chem Biol, Oct 2024
PubMed ID: 39283696
Targeting Ras-, Rho-, and Rab-family GTPases via a conserved cryptic pocket
Morstein J, Bowcut V, Fernando M, Yang Y, Zhu L, Jenkins ML, Evans JT, Guiley KZ, Peacock DM, Krahnke S*, Lin Z, Taran KA, Huang BJ, Stephen AG*, Burke JE, Lightstone FC, Shokat KM
Cell, Sep 2024
PubMed ID: 39255801
Improved production of class I phosphatidylinositol 4,5-bisphosphate 3-kinase
Messing S*, Widmeyer SRT*, Denson JP*, Mehalko J*, Wall VE*, Drew M*, Snead K*, Hong M*, Grose C*, Esposito D*, Gillette W*
Protein Expr Purif, 225:106582, Aug 2024
PubMed ID: 39173964
Functional and structural insights into RAS effector proteins
Mozzarelli AM, Simanshu DK*, Castel P
Mol Cell, Aug 2024
PubMed ID: 39025071
Determining KRAS4B-targeting compound specificity by top-down mass spectrometry D'Ippolito RA*, Scheidemantle GM*, Rabara D*, Abreu Blanco M*, Ramakrishnan N*, Widmeyer SRT*, Messing S*, Turner D*, Maciag AE*, Stephen AG*, Esposito D*, McCormick F, Nissley DV*, DeHart CJ*
Methods Mol Biol,2823:291-310, Jul 2024
PubMed ID: 39052227
Natural product graveoline modulates Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) membrane association: insights from advanced spectroscopic studiesCornilescu G*, Bindu L*, Sternicki L ,Chao FA*, Gillette WK*, Fer N*, Colombus J*, Castillo J*, Andrade Bonilla P*, Van QN*, Larsen E*, Hong M*, Burgan W*, Turbyville T*, Nissley DV*, Liu M, Quinn R, Jean-Francois FL*
ACS Pharmacol Transl Sci,7(7):1983-1995, Jul 2024
PubMed ID: 39022364